Emerging Concerns of Antifungal Resistance and the Need for Antifungal Stewardship
Recorded On: 04/26/2023
Description:
This session was part of the Sepsis Alliance AMR Conference 2023.
Much of the focus of Antimicrobial Stewardship programs has been on optimizing use of antibiotics in bacterial infections. However, with the rising rates of antifungal resistance, antifungal stewardship is also necessary. Unlike antibacterial drugs, there are only a limited number of drugs available to treat invasive fungal infections. In this session, the audience will learn about the current epidemiology of antifungal resistance worldwide, the current limitations of antifungal therapy, the effects of COVID-19 pneumonia on the risk of fungal infections, and what antifungal stewardship steps could limit the rise of antifungal resistance.
Learning Objectives:
At the end of the session, the learner should be able to:
- Discuss the epidemiology of antifungal resistance and how it affects human health;
- Identify the main drivers for the increasing trend in antifungal resistance;
- Describe preventative measures to curb the development of antifungal resistance.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Emi Minejima, PharmD
Associate Professor of Clinical Pharmacy
USC School of Pharmacy
Dr. Minejima received her PharmD degree from University of California, San Diego Skaggs School of Pharmacy in 2005 and completed both her residency training in pharmacy practice and infectious diseases pharmacotherapy at Huntington Hospital in Pasadena, CA. After residency, she joined the faculty at the University of Southern California, School of Pharmacy where she is currently an Associate Professor of Clinical Pharmacy. Her clinical practice is based at Los Angeles County/USC Medical Center where she helps run the antimicrobial stewardship program and is the director for PGY2 infectious diseases residency program. Her research interests include S. aureus infections and optimizing the use of antibiotics to improve care for the medically underserved population.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.0 contact hours.
Other healthcare professionals will receive a certificate of attendance for 0.75 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.